ASX:LCT

Living Cell Technologies (LCT) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
76,622 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LCT stock logo

About Living Cell Technologies Stock (ASX:LCT)

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Melbourne, Australia.

LCT Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Defining a city using cell-phone data
Here’s how to start a “Weekend Side Hustle” from your sofa
Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.
Living Cell Technologies Limited (LVCLF)
See More Headlines
Receive LCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Living Cell Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/19/2019
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Profitability

Net Income
$-2,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3,405.00

Miscellaneous

Outstanding Shares
1,640,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
0.48
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. David Richard Hainsworth (Age 50)
    CEO & Exec. Chairman
    Comp: $40k
  • Mr. Daya Uka
    Chief Financial Officer
  • Dr. Belinda Di Bartolo
    Chief Operations Officer
  • Dr. Carolyn M. Sue A.M. (Age 60)
    B.S., Ph.D., Member of Medical Advisory Board & Chief Medical Officer of NTCELL
    Comp: $50k
  • Mr. Madhukar Bhalla FCIS (Age 64)
    Company Sec.
    Comp: $40k
  • Dr. James A. Mckenna
    Chief Scientific Officer

LCT Stock Analysis - Frequently Asked Questions

How were Living Cell Technologies' earnings last quarter?

Living Cell Technologies Limited (ASX:LCT) released its earnings results on Tuesday, February, 19th. The company reported $0.00 earnings per share (EPS) for the quarter.

What other stocks do shareholders of Living Cell Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Living Cell Technologies investors own include eWellness Healthcare (EWLL), Energous (WATT), AllianceBernstein Global High Income Fund (AWF).

This page (ASX:LCT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners